This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bachman, K. E. Articles by Lengauer, C. Search for Related Content PubMed PubMed Citation Articles by Bachman, K. E. Articles by Lengauer, C.

¹ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, and Howard Hughes Medical Institute and ² Dipartimento Farmacochimico, Università di Bari, Bari, Italy

Requests for reprints: Kurtis E. Bachman, University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, 9-009 Bressier Research Building, Baltimore, MD 21201. Phone: 410-328-8076; Fax: 410-328-6559. E-mail: kbachman{at}som.umaryland.edu

The dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) is a heterocyclic amine and is a common byproduct of cooked meat and fish. Although most cells undergo apoptosis when exposed to this mutagen, subsets develop resistance. Rather than die, these resistant cells persist and accumulate mutations, thereby driving tumorigenesis of exposed organs within the gastrointestinal tract. By applying a high-throughput cell-based screen of 32,000 small molecules, we have identified a family of compounds that specifically inhibit the growth of PhIP-resistant cancer cells. These compounds may prove useful for the treatment or prevention of gastrointestinal tumors arising after exposure to PhIP and related carcinogens.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: K.E. Bachman is currently at University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201.

A. Bardelli is currently at The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino-Medical School, 10143 Candiolo, Italy.

Received 2/ 7/05; revised 3/14/05; accepted 3/28/05.